玄七通痹胶囊联合塞来昔布治疗类风湿关节炎的临床研究

目的 研究玄七通痹胶囊联合塞来昔布胶囊治疗类风湿关节炎的临床疗效.方法 选取2017年10月—2019年10月郑州市第六人民医院收治的120例类风湿关节炎患者,将120例患者随机分为对照组和治疗组,每组各60例.对照组口服塞来昔布胶囊,0.2 g/次,1次/d;治疗组患者在对照组治疗的基础上口服玄七通痹胶囊,4粒/次,...

Clinical study of Xuanqi Tongbi Capsules combined with celecoxib in treatment of rheumatoid arthritis

Objective To study the efficacy of Xuanqi Tongbi Capsules combined with Celecoxib Capsules in treatment of rheumatoid arthritis. Methods Patients(120 cases) with rheumatoid arthritis in Zhengzhou Sixth People’s Hospital from October 2017 to October 2019 were randomly divided into control and treatment groups, and each group had 60 cases. Patients in the control group were po administered with Celecoxib Capsules, 0.2 g/time, once daily. Patients in the treatment group were po administered with Xuanqi Tongbi Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacies were evaluated, and clinical symptoms and inflammatory factor in two groups were compared. Results After treatment, the total effective rate of the treatment group(96.67%) was significantly higher than that of the control group(86.00%)(P < 0.05). After treatment, the number of swollen joints, tenderness joints, morning stiffness time, and DAS28 score in the treatment group were significantly decreased(P < 0.05). And the number of swollen joints, number of tendered joints, time of morning stiffness, and the score of DAS28 in the treatment group were significantly lower than those in the control group(P < 0.05). After treatment, the serum levels of ESR, CRP, RF, and TNF-α in the two groups were significantly decreased(P < 0.05). And the serum levels of ESR, CRP, RF, and TNF-α in the treatment group were significantly higher than those in the control group(P < 0.05). Conclusion Xuanqi Tongbi Capsules combined with Celecoxib Capsules has clinical curative effect in treatment of rheumatoid arthritis, can improve the clinical symptoms, and reduce the serum level of inflammatory factors.